Literature DB >> 82615

Ultrastructural study of bleomycin-induced pulmonary changes in mice.

A W Jones, N L Reeve.   

Abstract

The pulmonary changes produced in mice given bleomycin intraperitoneally (twice weekly for 4 weeks, total dose 240 mg/kg) were examined by light and electron microscopy. Bleomycin damaged the pulmonary vessels and produced type I pneumocyte necrosis, resulting in non-uniform pulmonary fibrosis. The sequence of events leading to pulmonary fibrosis may be arbitrarily divided into three phases: firstly, a focal perivascular lesion consisting of interstitial oedema with plasma cell and lymphocyte infiltration; followed by the middle proliferative phase characterised by type I pneumocyte necrosis, intra-alveolar fibrin deposition, an increase in the numbers of type II pneumocytes and fibroblasts and an overall decrease in the alveolar diameter. The third phase consisted of organisation, with intra-alveolar and interstitial collagen formation and the synthesis of elastin. These phases, although occurring sequentially, did not bear a constant time relationship to the dosage schedule, for new early focal lesions continued to appear throughout the period of the experiment. These ultrastructural changes are not specific for bleomycin, but represent a general reaction of the lung to injury. The exact mechanism whereby bleomycin produces the lung damage has yet to be ascertained.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 82615     DOI: 10.1002/path.1711240407

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  12 in total

1.  Pulmonary fibrosis: a cellular overreaction or a failure of communication?

Authors:  D Sheppard
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

2.  Suppression of von Hippel-Lindau Protein in Fibroblasts Protects against Bleomycin-Induced Pulmonary Fibrosis.

Authors:  Qiyuan Zhou; Tianji Chen; Wei Zhang; Melike Bozkanat; Yongchao Li; Lei Xiao; Richard B van Breemen; John W Christman; Jacob I Sznajder; Guofei Zhou
Journal:  Am J Respir Cell Mol Biol       Date:  2016-05       Impact factor: 6.914

Review 3.  Lung damage from cytotoxic drugs.

Authors:  C H Collis
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

4.  Experimental bleomycin lung in mice. A contribution to the pathogenesis of pulmonary fibrosis.

Authors:  E Fasske; K Morgenroth
Journal:  Lung       Date:  1983       Impact factor: 2.584

5.  Pulmonary toxicity of the combination of bleomycin and peplomycin--an experimental study in rats.

Authors:  G Mall; A Burkhardt
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Prevention of bleomycin-induced fibrosing alveolitis with indomethacin: stereological studies on rat lungs.

Authors:  G Mall; P Zimmermann; I Siemens; A Burkhardt; H F Otto
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

7.  Mechanisms of pulmonary fibrosis. Spontaneous release of the alveolar macrophage-derived growth factor in the interstitial lung disorders.

Authors:  P B Bitterman; S Adelberg; R G Crystal
Journal:  J Clin Invest       Date:  1983-11       Impact factor: 14.808

Review 8.  The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis.

Authors:  Benjamin D Bringardner; Christopher P Baran; Timothy D Eubank; Clay B Marsh
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

9.  Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis.

Authors:  P F Piguet; M A Collart; G E Grau; Y Kapanci; P Vassalli
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

10.  Activation of the canonical bone morphogenetic protein (BMP) pathway during lung morphogenesis and adult lung tissue repair.

Authors:  Alexandros Sountoulidis; Athanasios Stavropoulos; Stavros Giaglis; Eirini Apostolou; Rui Monteiro; Susana M Chuva de Sousa Lopes; Huaiyong Chen; Barry R Stripp; Christine Mummery; Evangelos Andreakos; Paschalis Sideras
Journal:  PLoS One       Date:  2012-08-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.